Literature DB >> 19419768

Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study.

Beáta Tóth1, Alla Volokha, Alexander Mihas, Malgorzata Pac, Ewa Bernatowska, Irina Kondratenko, Alexander Polyakov, Melinda Erdos, Srdjan Pasic, Michaela Bataneant, Anna Szaflarska, Kristina Mironska, Darko Richter, Katarina Stavrik, Tadej Avcin, Gabriella Márton, Kálmán Nagy, Beáta Dérfalvi, Miklós Szolnoky, Agnes Kalmár, Michael Belevtsev, Marina Guseva, Aurica Rugina, Gergely Kriván, László Timár, Zoltán Nyul, Bernadett Mosdósi, Lidija Kareva, Sonja Peova, Liudmyla Chernyshova, Ioan Gherghina, Margit Serban, Mary Ellen Conley, Luigi D Notarangelo, C I Edvard Smith, Jacques van Dongen, Mirjam van der Burg, László Maródi.   

Abstract

Primary immunodeficiency disorders are a recognized public health problem worldwide. The prototype of these conditions is X-linked agammaglobulinemia (XLA) or Bruton's disease. XLA is caused by mutations in Bruton's tyrosine kinase gene (BTK), preventing B cell development and resulting in the almost total absence of serum immunoglobulins. The genetic profile and prevalence of XLA have not previously been studied in Eastern and Central European (ECE) countries. We studied the genetic and demographic features of XLA in Belarus, Croatia Hungary, Poland, Republic of Macedonia, Romania, Russia, Serbia, Slovenia, and Ukraine. We collected clinical, immunological, and genetic information for 122 patients from 109 families. The BTK gene was sequenced from the genomic DNA of patients with a high susceptibility to infection, almost no CD19(+) peripheral blood B cells, and low or undetectable levels of serum immunoglobulins M, G, and A, compatible with a clinical and immunological diagnosis of XLA. BTK sequence analysis revealed 98 different mutations, 46 of which are reported for the first time here. The mutations included single nucleotide changes in the coding exons (35 missense and 17 nonsense), 23 splicing defects, 13 small deletions, 7 large deletions, and 3 insertions. The mutations were scattered throughout the BTK gene and most frequently concerned the SH1 domain; no missense mutation was detected in the SH3 domain. The prevalence of XLA in ECE countries (total population 145,530,870) was found to be 1 per 1,399,000 individuals. This report provides the first comprehensive overview of the molecular genetic and demographic features of XLA in Eastern and Central Europe.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419768     DOI: 10.1016/j.molimm.2009.03.012

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  16 in total

1.  Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?

Authors:  László Maródi; Jean-Laurent Casanova
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  Nationwide survey of patients with primary immunodeficiency diseases in Japan.

Authors:  Masataka Ishimura; Hidetoshi Takada; Takehiko Doi; Kousuke Imai; Yoji Sasahara; Hirokazu Kanegane; Ryuta Nishikomori; Tomohiro Morio; Toshio Heike; Masao Kobayashi; Tadashi Ariga; Shigeru Tsuchiya; Shigeaki Nonoyama; Toshio Miyawaki; Toshiro Hara
Journal:  J Clin Immunol       Date:  2011-09-29       Impact factor: 8.317

Review 3.  The spread of the J Project.

Authors:  Zsuzsa Horváth; Nima Rezaei; Ismail Reisli; Irina Tuzankina; Nurzhan Otarbayev; Panteley Popandopulo; László Maródi
Journal:  J Clin Immunol       Date:  2013-05-19       Impact factor: 8.317

4.  X-linked agammaglobulinemia with hearing impairment, dystonia-parkinsonism, and progressive neurodegeneration.

Authors:  Aloysius Domingo; Thomas G P M Schmidt; Ela Barcelon; Marissa Lukban; Ana Westenberger; Christine Klein
Journal:  J Neurol       Date:  2014-10-01       Impact factor: 4.849

Review 5.  Lung Disease in Primary Antibody Deficiencies.

Authors:  Edith Schussler; Mary B Beasley; Paul J Maglione
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

6.  Bruton's agammaglobulinemia in an adult male due to a novel mutation: a case report.

Authors:  Yuanda Xu; Qi Qing; Xuesong Liu; Sibei Chen; Ziyi Chen; Xuefeng Niu; Yaxia Tan; Weiqun He; Xiaoqing Liu; Yimin Li; Rongchang Chen; Ling Chen
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

7.  Gastrointestinal Manifestations in X-linked Agammaglobulinemia.

Authors:  Sara Barmettler; Iris M Otani; Jasmit Minhas; Roshini S Abraham; Yenhui Chang; Morna J Dorsey; Zuhair K Ballas; Francisco A Bonilla; Hans D Ochs; Jolan E Walter
Journal:  J Clin Immunol       Date:  2017-02-24       Impact factor: 8.317

8.  Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy.

Authors:  A Stubbs; C Bangs; B Shillitoe; J D Edgar; S O Burns; M Thomas; H Alachkar; M Buckland; E McDermott; G Arumugakani; S Jolles; R Herriot; P D Arkwright
Journal:  Clin Exp Immunol       Date:  2017-11-03       Impact factor: 4.330

Review 9.  Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management.

Authors:  Paul J Maglione
Journal:  Immunol Allergy Clin North Am       Date:  2020-06-09       Impact factor: 3.479

Review 10.  Agammaglobulinemia: from X-linked to Autosomal Forms of Disease.

Authors:  Melissa Cardenas-Morales; Vivian P Hernandez-Trujillo
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-09       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.